Shares of Merck & Co. Inc. MRK rallied 2.08% to $89.50 Friday, on what proved to be an all-around rough trading session for ...

Merck (MRK) stock in focus as anti-cancer agent Welireg is approved in the EU for kidney tumor conditions, VHL disease and ...

The global Microcarriers market, valued at US$2.03 billion in 2023, is forecasted to grow at a robust CAGR of 8.0%, reaching US$2.08 billion ...

The transaction, expected to close in the first half of this year, will cost Novartis $925 million upfront with potential ...

Merck has not shied away from splashy takeovers in the past. In 2015, the company agreed to buy U.S. lab equipment supplier ...

TD Cowen downgraded Merck (MRK) to Hold from Buy with a price target of $100, down from $121. The firm says its Buy thesis “broke down” with ...

With power increasingly dispersed globally, and as the lines between international and domestic policy get more blurred, Europe requires a coherent approach to deepen partnerships with new coalitions ...

On Tuesday, Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of ...

Europe is facing a triple crisis – Trump’s re-election is the shock therapy it needs Trump’s re-election has come at a particularly bad time for the European defence industrial base. European ...

Welcome to the Merck & Company Q4 sales and earnings conference ... There remains a need to protect more individuals from HPV-related cancers. In Europe, the Committee for Medicinal Products ...